ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)

Inclusion Criteria: * Male or female outpatients at least 18 years of age * Symptoms of OAB for a minimum of 3 consecutive months prior to study entry; severity of OAB (as defined by patient reported symptoms) for a minimum of one month prior to study entry * Ability to use a toilet independently and without difficulty * No treatment with any medication against OAB during the 4 weeks prior to study entry * Written informed consent Exclusion Criteria: * Breastfeeding women, pregnant women or women who intend to become pregnant during the study or women of childbearing potential who are sexually active and not practicing a highly reliable method of birth control * Any local pathology, that might cause the bladder symptoms * Significant stress urinary incontinence or mixed stress/urgency incontinence * Any neurological disease affecting bladder function or muscle strength * Patient history of any lower urinary tract surgery or previous pelvic irradiation * Local administration of botulinum toxin within the last 9 months in the lower urinary tract * Start or change of a behavioral bladder training program * Post voiding residual volumes larger than 250ml or symptoms of clinically relevant bladder outlet obstruction * Nocturial polyuria * History of liver disease and/or impaired liver function * Cholestasis * Chronic alcohol or drug abuse * Evidence of significantly impaired renal function ( * Diabetes mellitus (type I or II) with significant peripheral neuropathy and/or polyuria * Inflammatory bowel disease such as Crohn's disease, or ulcerative colitis * Uncontrolled narrow angle glaucoma * Chronic use of carbamazepine or paracetamol * Participation in any drug study in the preceding 3 months * Concomitant treatment with strong CYP3A4 inhibitors * History or evidence of relevant cardiovascular or cerebrovascular disorders